Literature DB >> 3907641

[The behavior of blood clotting and its inhibitors under long term treatment with 5,6-benzo-alpha-pyrone (coumarin). Double blind study].

H Köstering, B Bandura, H A Merten, J U Wieding.   

Abstract

The analyses on hemostaseological variables are recorded in connection with blood tests in the course of a double-blind study in 41 patients suffering from chronic venous insufficiency of higher degrees of severity. They were treated in addition to compression measures with two active ingredients, a coumarin (5,6-benzo-alpha-pyrone)/troxerutin combination (Venalot Depot) (n = 20) or benzarone (n = 21) receiving 3 X 2 dragees daily for 6 weeks. Good clinical efficacy and the improvement of symptoms were observed together with almost no side-effects. The coagulation analysis showed no influence of the active principles on the global coagulation or the clotting factors and the inhibitors and factors of the fibrinolysis. In particular there was no phenprocoumon-like effect on the blood clotting system.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3907641

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  3 in total

Review 1.  Phlebotonics for venous insufficiency.

Authors:  Maria José Martinez-Zapata; Robin W M Vernooij; Sonia Maria Uriona Tuma; Airton T Stein; Rosa M Moreno; Emilio Vargas; Dolors Capellà; Xavier Bonfill Cosp
Journal:  Cochrane Database Syst Rev       Date:  2016-04-06

Review 2.  Safety Profile of Nutraceuticals Rich in Coumarins: An Update.

Authors:  Simona Codruta Heghes; Oliviu Vostinaru; Cristina Mogosan; Doina Miere; Cristina Adela Iuga; Lorena Filip
Journal:  Front Pharmacol       Date:  2022-01-24       Impact factor: 5.810

3.  Phlebotonics for venous insufficiency.

Authors:  Maria José Martinez-Zapata; Robin Wm Vernooij; Daniel Simancas-Racines; Sonia Maria Uriona Tuma; Airton T Stein; Rosa Maria M Moreno Carriles; Emilio Vargas; Xavier Bonfill Cosp
Journal:  Cochrane Database Syst Rev       Date:  2020-11-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.